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Background: MicroRNA let-7i has been proven to be down-regulated in many human malignancies and correlated
with tumor progression and anticancer drug resistance. Our study aims to characterize the contribution of miRNA
let-7i to the initiation and malignant progression of locally advanced gastric cancer (LAGC), and evaluate its
possible value in neoadjuvant chemotherapeutic efficacy prediction.
Methods: Eighty-six previously untreated LAGC patients who underwent preoperative chemotherapy and radical
resection were included in our study. Let-7i expression was examined for pairs of cancer tissues and corresponding
normal adjacent tissues (NATs), using quantitative RT-PCR. The relationship of let-7i level to clinicopathological
characteristics, pathologic tumor regression grades after chemotherapy, and overall survival (OS) was
also investigated.
Results: Let-7i was significantly down-regulated in most tumor tissues (78/86: 91%) compared with paired NATs
(P < 0.001), and low levels of let-7i were significantly correlated with local invasion, lymphatic metastasis, and poor
pathologic tumor response. Multivariate Cox regression analysis revealed that low let-7i expression was an
unfavorable prognostic factor of OS (hazard ratio (HR) = 2.316, P =0.024) independently of other clinicopathological
factors, including tumor node metastasis (TNM) stage (HR = 3.226, P = 0.013), depth of infiltration (HR = 4.167,
P < 0.001), and lymph node status (HR = 2.245, P = 0.037).
Conclusions: These findings indicate that let-7i may be a good candidate for use a therapeutic target and a
potential tissue marker for the prediction of chemotherapeutic sensitivity and prognosis in LAGC patients.
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Despite its declining incidence in Western countries
over the past 50 years, gastric cancer (GC) remains the
second most frequently diagnosed cancer worldwide,
with more than 600,000 deaths per year [1]. Complete
resection of the primary tumor and involved lymph
nodes (LNs) is considered the only potentially curative
treatment for GC. However, the majority of GC pa-
tients present an advanced stage when diagnosed, and
the 5-year survival rate is poor, even in patients receiving
radical resection [2]. It has been confirmed that* Correspondence: manuscripttang@163.com
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reproduction in any medium, provided the orpreoperative chemotherapy could improve progression-
free and overall survival (OS) in patients with operable
advanced GC [3]. However, like antibiotic-resistant bac-
teria, tumor cells often show intrinsic or acquired resist-
ance to anticancer drugs, leading to inefficacy of
chemotherapy. Although previous investigations have
identified a variety of molecules associated with the initi-
ation, progression, and drug response of GC, its precise
molecular mechanisms remain unclear, and biologic
markers with high sensitivity and specificity for the diag-
nosis and chemotherapeutic response prediction of GC
are still lacking.
MicroRNAs (miRNAs) are naturally occurring, small,
non-coding RNAs that mediate gene expression through
complimentary binding of the 30 untranslated regionsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The binding results in degradation of the mRNA and in-
hibition of translation [5]. More than 700 miRNA
sequences have been revealed in the human genome in
miRBase version 13.0, and this number is predicted to
double because more miRNAs are awaiting experimental
validation. It is now evident that miRNAs have very im-
portant regulatory functions in some basic biological
processes, such as development, cellular differenti-
ation, proliferation, and apoptosis. In addition, about
50% of miRNAs are located in cancer-associated gen-
omic regions or at fragile sites [6], and they are fre-
quently misexpressed or mutated in cancer patients
and regarded as oncogenes or tumor suppressor
genes [7-9]. Furthermore, increasing amounts of evi-
dence indicate that miRNAs are associated with sen-
sitivity or resistance to chemotherapeutic drugs, such
as cisplatin or 5-fluorouracil in various cancer types
[10-13].
Let-7 was originally identified in the nematode
Caenorhabditis elegans as a regulator of developmental
timing and cellular proliferation [14]. Subsequent work
revealed that both its sequence and its function were
highly conserved in mammals. As one of the first tumor
suppressor miRNAs, let-7 has been proven to be down-
regulated in many human malignancies and correlates
with tumor progression and clinical prognosis [15-17].
Specifically, miRNA let-7i, a let-7 family member, was
confirmed to play an important role in anticancer drug
resistance in vivo and in vitro [13,18]. However, to our
knowledge, no attention has been paid to the value of
let-7i in neoadjuvant chemotherapeutic efficacy predic-
tion in GC patients.
In this study, we compared let-7i expression in GC
with non-tumor tissues, and analyzed its clinicopatholo-
gic value. In addition, we investigated the possibility of
let-7i as a novel biomarker in predicting tumor response
and OS in advanced GC patients treated with neoadju-
vant chemotherapy and surgery.
Methods
Patients and samples
A total of 86 LAGC patients, who had been treated with
preoperative chemotherapy and surgery from July 2005
to March 2007, were enrolled in our study. The median
age at diagnosis was 59 years (range, 37 to 69 years). All
patients received three cycles of neoadjuvant chemother-
apy (FOLFOX 4) and a radical resection. Chemotherapy
consisted of 85 mg/m2 oxaliplatin on day 1, and 200
mg/m2 folinic acid as a 2h infusion followed by a 400
mg/m2 bolus 5-Fu and a 22h infusion of 5-Fu 600 mg/m2
on days 1 and 2 every other week. Curative resection was
performed within 2 weeks after the last application of
chemotherapy. Patient eligibility also required the fulfilmentof the following criteria: age 18 to 70 years; clinical
tumor stage T2-4, N1-2, or M0, according to the
American Joint Committee for Cancer (AJCC) [19];
performance status of 0 or 1, based on the Eastern
Cooperative Oncology Group (ECOG) criteria; no evi-
dence of distant metastases; adequate hematologic, hep-
atic, renal, and cardiac function. Pretreatment staging
procedures included physical examination, chest X-ray,
abdominal computed tomography (CT) scan, and endo-
scopic ultrasonography. Histological grade was assessed
according to the World Health Organization criteria.
Patients were excluded if they had a previous or second-
ary malignancy, were pregnant, had active bleeding
from the upper gastrointestinal tract, had uncontrolled
and serious infection, or had previously undergone radi-
ation therapy, chemotherapy, or immunotherapy. This
study was approved by the medical ethics committee of
our institution, and signed informed consent was
obtained from all patients.
Tissue samples were obtained before and after treat-
ment. Prior to neoadjuvant chemotherapy, pairs of pri-
mary gastric tumors and normal adjacent tissues (NATs)
>3 cm from the cancer tissue) were collected by gastro-
scopic biopsies from each patient. Biopsies were flash
frozen and stored at −80°C in liquid nitrogen prior to
analysis of let-7i expression. After operation, the
patient’s response to chemotherapy was assessed histolo-
gically using resected tissue.
RNA extraction and quantitative real-time PCR
Total RNA from pretreatment GC and NAT biopsies
was isolated using TRIzolW reagent (Invitrogen Corp,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. RNA quality and quantity were assessed
using a Bioanalyzer 2100 system (Agilent Technologies
Inc. Santa Clara, CA, USA). The let-7i and RNA U6 (as
an internal control) specific complementary DNA were
synthesized from total RNA using gene-specific primers
according to the TaqManW miRNA assay protocol (Ap-
plied Biosystems, Foster City, CA, USA). Reverse tran-
scription reactions contained 10 ng total RNA, 50 nmol/
l stem-loop RT primer, 1 × RT buffer, 0.25 mmol/l each
deoxynucleotide triphosphate (dNTP), 3.33 units/μl
MultiScribeW reverse transcriptase and 0.25 units/μl
RNase inhibitor in a total volume of 7.5 μl (Applied Bio-
systems). Reactions were incubated in a 96-well plate for
30 min at 16°C, flowed by 30 min at 42°C and 5 min at
85°C, and then held at 4°C.
Real-time polymerase chain reaction (RT-PCR) was
performed using the 7500 real-time PCR system (Ap-
plied Biosystems). Reactions were carried out in 96-well
plates in a total volume of 10 μl (0.67 μl RT products,
1 × TaqManW Universal PCR master mix, and 1 μl Taq-
ManW miRNA assay primer and probe mix). The
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followed by 45 cycles of 95°C for 15 s and 60°C for 10
min. All samples were processed in triplicate. The
threshold cycle (Ct) was defined as the fractional cycle
number at which the fluorescence passed the fixed
threshold. The amount of let-7i relative to U6 RNA
was calculated using the equation 2−ΔCt where ΔCt =
(Ctlet-7i − CtU6). The fold change in let-7i expression
between GC and NATs was determined by the 2−ΔΔCt
method, where ΔΔCt = (Ctlet-7i − CtU6) (in tumor
samples) − (Ctlet-7i − CtU6) (in NATs) [20].Pathologic response evaluation
After resection, all specimens were cross-sectioned seri-
ally at 0.5 cm intervals. Two pathologists blinded to let-
7i expression reviewed the slides. The Becker score [21],
based on an estimation of the percentage of residual
tumor tissue in relation to the macroscopically identifi-
able tumor bed, was used to evaluate pathologic re-
sponse. Tumor regression was classified into three
grades, as follows: Grade 1, complete or subtotal regres-
sion (<10% residual tumor per tumor bed); Grade 2, par-
tial tumor regression (10% to 50% residual tumor per
tumor bed); and Grade 3, minimal or no tumor regres-
sion (>50% residual tumor per tumor bed). All patients
with grade 1 or 2 regression were classified as respon-
ders, while grade 3 was defined as a pathologic non-
response.Follow-up
Follow-up was performed at 3-month intervals for 1
year, then at 6-month intervals for 3 years, and yearly
thereafter. Follow-up consisted of a physical examin-
ation, a complete blood count, liver function tests,
serum tumor markers, and an abdominal and pelvic CT
scan. The patients also underwent chest X-rays and gas-
troscopy every 6 months, regardless of their follow-up
schedule. Survival time was calculated from the date of
the first neoadjuvant chemotherapy to the date of death
or the last follow-up.Figure 1 Down-regulation of miRNA let-7i (2–ΔΔCt) in gastric
cancer tissues compared with corresponding normal controls
(P < 0.001, Wilcoxon matched-pairs test).Statistics
Statistical analysis was performed using SPSSW, version
17.0 (SPSS Inc., Chicago, USA) for WindowsW. Compari-
sons of let-7i levels in GC versus NATs were made with
the Wilcoxon matched-pairs test. Clinicopathological
factors and let-7i levels were analyzed by one-way ana-
lysis of variance (ANOVA). The joint effect of covari-
ables was examined using the Cox proportional hazard
regression model. All tests were two-tailed, and the sig-
nificance level was set at P < 0.05.Results
Let-7i expression in GC tissues and its association with
clinicopathological characteristics before chemotherapy
The result of quantitative RT-PCR verified that let-7i
was significantly down-regulated in most tumor tissues
(78/86; 91%) compared with the paired NATs (P < 0.001,
Wilcoxon matched-pairs test, Figure 1), with a median
fold change of 0.28-fold. Patient characteristics with re-
spect to decreased let-7i expression are shown in Table 1.
Low levels of let-7i correlated significantly with local in-
vasion and lymphatic metastasis. No correlation was
observed between let-7i level and other clinicopathologi-
cal features, such as age, sex, tumor site, or cell
differentiation.
Correlation between let-7i expression and tumor
response and overall survival
According to the three-point pathologic regression grade
system, 17 of the 86 specimens were classified as grade
1, 38 as grade 2, and 31 as grade 3. In total, 55 patients
were categorized as pathologic responders and 31 as
non-responders. Let-7i expression levels in pathologic
responders were significantly higher than in non-
responders (P < 0.001, Table 1).
At the time of scheduled analysis (January 2012), 9 of
the 86 patients were still alive, and the other patients
had already passed away. The median follow-up time
was 35 months, ranging from 9 to 76 months. Aside
from let-7i expression (P = 0.016, (hazard ratio (HR) =
2.436), univariate Cox proportional hazard regression
analysis revealed that tumor node metastasis (TNM)
stage (P = 0.003, HR = 3.478), differentiation degree
(P = 0.029, HR = 2.128), depth of infiltration (P < 0.001,
HR = 5.691), and lymph node status (P = 0.008,
HR = 2.936) were also predictive factors for prognosis









≤59 43 0.33 ± 0.14 0.388
>59 43 0.26 ± 0.19
Sex
Male 57 0.38 ± 0.35 0.215
Female 29 0.24 ± 0.16
Local invasion
T2 19 0.87 ± 0.71 <0.001
a
T3 35 0.40 ± 0.25 0.002
b
T4 32 0.13 ± 0.11
Lymphatic metastasis
N1 33 0.49 ± 0.44 0.003
N2 53 0.18 ± 0.15
Tumor site
Upper 22 0.35 ± 0.30 0.262
Middle 30 0.25 ± 0.23
Lower 34 0.30 ± 0.22
Cell grade
Poor 60 0.27 ± 0.18 0.476
Moderate 26 0.32 ± 0.28
Pathologic tumor response
Responder 55 0.59 ± 0.46 <0.001
Non-responder 31 0.16 ± 0.10
a Compared with T3 and T4; b Compared with T4.
Table 2 Univariate and multivariate Cox proportional
hazard regression analyses of the relationship between
miRNA let-7i levels, clinicopathological characteristics,
and prognosis in LAGC patients
Variable Subset Hazard ratio P value
Univariate analysis (n = 86)
Age ≥59 versus <59 0.665 0.205
Sex Male versus female 0.715 0.313
Let-7i level Fold change 2.436 0.016
TNM stage II versus III 3.478 0.003







Lymph node metastasis N1 versus N2 2.936 0.008
Multivariate analysis (n = 86)
Age ≥59 versus <59 0.622 0.356
Sex Male versus female 0.576 0.463
Let-7i level Fold change 2.316 0.024
TNM stage II versus III 3.226 0.013
Depth of infiltration T2 versus T3-4 4.167 <0.001






Lymph node metastasis N1 versus N2 2.245 0.037
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regression analysis confirmed that low-level let-7i
expression (P =0.024, HR = 2.316) was an unfavorable
prognostic factor independent of other clinicopatho-
logical factors, including TNM stage (P = 0.013,
HR = 3.226), depth of infiltration (P < 0.001, HR = 4.167),
and lymph node status (P = 0.037, HR = 2.245; Table 2).
Discussion
The discovery of miRNAs has substantially changed the
view on gene regulation, and new findings over the past
few years have catapulted miRNAs to the center stage of
cancer molecular biology. In this study, we compared
let-7i expression levels in GC with NATs. By using real-
time RT-PCR, we found that let-7i was significantly
down-regulated in cancer tissues. In addition, a low level
of let-7i was closely correlated with local invasion and
lymphatic metastasis. Our findings are in agreement
with some previous studies. For example, aberrant
expression of let-7 has been proven by a number of
groups and in various types of tumors, such ascholangiocarcinoma [22], lung cancer [15], epithelial
ovarian cancer [23], breast cancer [24], and colon cancer
[17]. Reduced let-7 expression has also been associated
with tumor progression and shortened postoperative
survival in lung and ovarian cancer patients [15,16,23].
Taken together, these results may help to explain the im-
portant role of let-7i not only in tumor pathogenesis but
also in cancer progression and invasion in GC patients.
Our study also revealed the potential value of let-7i in
predicting pathologic tumor response and OS in GC
patients following neoadjuvant chemotherapy for the
first time. Compared with postoperative chemotherapy,
neoadjuvant chemotherapy has some theoretical bene-
fits, including down-staging the primary tumor so as to
increase the likelihood of a curative resection and per-
forming an early treatment to the possible distant micro-
metastases. However, the selection of appropriate
patients who will benefit from chemotherapy is still a
major challenge in oncology. If chemotherapy is ineffect-
ive, the patient is needlessly exposed to its adverse
effects and quality of life can be diminished. While many
studies show a correlation between miRNAs and car-
cinogenesis and cancer progression, a few also reveal a
role for miRNAs in cancer chemoresistance. In terms of
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of NCI-60 human cancer cell lines was increased or
decreased when transfected with active let-7i precursor
or anti- let-7i oligomer. Yang et al. [13] confirmed
that let-7i expression was significantly reduced in
chemotherapy-resistant ovarian cancer patients in com-
parison with chemotherapy-sensitive patients, and that
up-regulated let-7i could increase the sensitivity of ovar-
ian and breast cancer cells to cisplatinum. Further, the
let-7 family could also alter sensitivity to radiotherapy in
lung cancer cells, as previously reported by Slack’s group
[25]. In this study, we observed that decreased let-7i ex-
pression was significantly associated with poorer re-
sponse to chemotherapy and shorter OS of patients with
GC. Since survival has traditionally been the gold stand-
ard for the primary endpoint of clinical trials of cancer
therapies [26,27], and pathologic tumor regression grade
is closely correlated with actual oncologic outcomes
[28], our results strongly suggest that let-7i might be a
novel therapeutic target for modulating chemotherapeu-
tic sensitivity and a potent biomarker for predicting
tumor response and survival in advanced GC patients.
The molecular genetic basis of carcinogenesis, cancer
progression and drug resistance is complex. Previous re-
search has already discovered a variety of molecules tar-
geted by the let-7 family and involved in its tumor
suppression function. First, several well-characterized
oncogenes, such as RAS [29], MYC [30], IMP1 [31],
HMGA2 [32], NF2 [22], E2F2, and CCND2 [33], have
been confirmed as targets of human let-7. In addition,
microarray experiments have also identified a large set
of cell-cycle-associated genes that are responsive to
regulation of let-7 levels. Although some of these effects
might be indirect, at least two genes, CDC25A and
CDK6, have been found to have a direct modulation by
let-7 at cell level in subsequent analysis [34]. Finally,
Chen et al. reported that let-7i could regulate toll-like
receptor 4 expression and contribute to cholangiocyte
immune responses against Cryptosporidium parvum in-
fection [35]. Some useful targets have been identified
during the past few years; however, there is no ‘one-to-
one’ connection between miRNAs and target mRNAs.
An average miRNA may have more than 100
targets, and one mRNA might be regulated by a variety
of miRNAs. Therefore, the effect of let-7i on cancer de-
velopment and chemoresistance is still not well under-
stood, and the determination of more molecular
characteristics of let-7i remains an important aim of fu-
ture investigations.
Conclusion
In conclusion, we revealed different let-7i expression be-
tween GC and paired non-tumorous tissues. A low level
of let-7i was also associated with tumor progression,chemotherapy resistance, and shorter OS. These findings
indicate that let-7i may be a good candidate for use as a
therapeutic target and a potential tissue marker for the
prediction of chemotherapeutic sensitivity and prognosis
in LAGC patients.
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